1WCM
INSY

12 West Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

12 West Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-623,791
Closed -$8.07M – 25
2016
Q2 		$8.07M Hold
623,791
– – 1.3% 15
2016
Q1 		$9.97M Buy
+623,791
New +$11.8M 1.39% 15

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

12 West Capital Management's INSY Position: Q3 2016 in Review

12 West Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q3 2016, closing a stake of 623,791 shares — an estimated $8.07M sold.

12 West Capital Management first reported a position in INSY in Q1 2016 and held it in 2 quarters. The position peaked at $9.97M in Q1 2016. 138 funds tracked by Wall St. Rank hold INSY as of Q3 2016.

  • 12 West Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • 12 West Capital Management sold 623,791 Insys Therapeutics, Inc. shares in Q3 2016, an estimated $8.07M.
  • 12 West Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • 12 West Capital Management's Insys Therapeutics, Inc. position peaked at $9.97M in Q1 2016.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2016.

Based on 12 West Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.